Psychiatr. praxi. 2022;23(3):187-190 | DOI: 10.36290/psy.2022.035

Efficacy/safety of olanzapine orodispersible tablets

MUDr. Jonáš Boček
Klinika psychiatrie, LF UP v Olomouci a FN Olomouc

Olanzapine is an antipsychotic medication. Its indications include psychotic disorders and manic phases in bipolar affective disorder. The mechanism of action is multi-receptor, which results in its effects not only on the positive symptomatology of psychotic diseases. The dispersible form of olanzapine is bioequivalent to the classic tablet form. The efficacy and safety of this variant make the dispersible form a suitable choice for various psychiatric conditions.

Keywords: olanzapine, dispersible form, efficacy, safety.

Accepted: October 11, 2022; Published: October 25, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boček J. Efficacy/safety of olanzapine orodispersible tablets. Psychiatr. praxi. 2022;23(3):187-190. doi: 10.36290/psy.2022.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mohr P. Antipsychotika. In Mohr P, Klinická psychofarmakologie. Praha; Maxdorf, s. r. o. 2017;111-187.
    2. Correll CU. From receptor pharmacology to improved outcomes in individualising the selection, dosing and switching of antipsychotics. Eur Psychiatry. 2010;(suppl 2):12-21. Go to original source... Go to PubMed...
    3. Stahl S. Olanzapine. In: Stahl S. Stahl's Essential Psychopharmacology, Prescribe's Guide. United Kingdom: Clays, St Ives plc. 2017;527-535.
    4. SÚKL, Státní ústav pro kontrolu léčiv [Internet]. Souhrn údajů o přípravku. Zyprexa; c2022. [cited 2022 Aug 28]. Available from: https://www.sukl.cz/.
    5. Gajdziok J, Rabišková M. Orálně dispergovatelné lékové formy a technologie jejich výroby. Česká a slovenská Farmacie. 2010; 59(6):251-255.
    6. Montgomery W, Treuer T, Karagianis J, et al. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient preference and adherence. 2012; 6:109. Go to original source... Go to PubMed...
    7. Kinon BJ, Hill A, Liu H, et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non­‑compliant patients with schizophrenia. International Journal of Neuropsychopharmacology. 2003;6.2:97-102. Go to original source... Go to PubMed...
    8. Kuramochi M, Nishiuma S, Tanji U, et al. Actual state of use of orally disintegrating olanzapine tablets in patients with acute­‑stage schizophrenia. Rinsho Seishin Yakuri. 2009;12:2159-2168.
    9. Chartier F, Rouillon F, Lukasiewicz M, et al. Effectiveness of olanzapine coated and orally disintegrating tablets in a 1-year European observational study. European Neuropsychopharmacology. 2010;20(Suppl 3):508-509. Go to original source...
    10. Van Heeringen C, Vandendriessche F, Van Vleymen B, et al. The effect of using orally disintegrating olanzapine tablets on agitation, cooperation and nurses workload in psychiatric patients. Acta Psychiatrica Belgica. 2006;106:14-19.
    11. San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS neuroscience & therapeutics. 2008;14(3):203-214. Go to original source... Go to PubMed...
    12. Pascual, JC, Perez V, Martin, JLR, et al. Olanzapine orally­‑disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas españolas de psiquiatría. 2007;35(1).
    13. Bitter I, Treuer T, Dilbaz N, et al. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. The World Journal of Biological Psychiatry. 2010; 11(7):894-903. Go to original source... Go to PubMed...
    14. Jibson M. Second­‑generation antipsychotic medications: Pharmacology, administration, and side effects. [Internet]. 2022 [cited 2022 Aug 26]. Available from: https://www.uptodate.com/.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.